Both RUT and W-S stain were positive was diagnosed as Helicobacter pylori infection.Contrast the diagnostic accuracy of atrophic gastritis among the three groups. Compare the differences of gastric mucosa features which suggest Helicobacter pylori infection among the three group. Results: Results: 85 cases of group I,88.3% were Hp positive,25.8% were atrophy,1.1% were intestinal metaplasia and 4.4% were heterogenesis.108 cases of group II,31.5% were Hp positive,49%

were atrophy,27.8% were intestinal metaplasia and 10.2% were heterogenesis; 15 cases of group III,26.7% were Hp positive,93.3%were atrophy,60% were intestinal metaplasia and 26% were heterogenesis.14 cases of the 15 cases in the III group, the region which got grey and thinner were atrophic see more Silmitasertib gastritis,the region which surrouding erythrophlogosis

gastric mucosa were chronic inflammation.Compared group I with group II, both of the cases of Hp infection and atrophic gastritis were differences (P < 0.05).Among the group comparison, the cases of atrophic gastritis were significantly differences(P < 0.05). Conclusion: Conclusion: Regions of gastric mucosa with a obvious boundary got thinner and blood vessel could be seen,the description above could be the specific manifestation of atrophic gastritis. Key Word(s): 1. Atrophic gastritis; 2. Helicobacter pylori; 3. endoscopy; Presenting BCKDHA Author: RAPAT PITTAYANON Additional Authors: WIRIYAPORN RIDTITID, NUTTAPHAT NAMJUD, RATHA-KORN VILAICHONE, VAROCHA MAHACHAI Corresponding Author: VAROCHA MAHACHAI Affiliations: Chulalongkorn University; Thammasart University Objective: Optimal H.pylori eradication therapy varies among different geographical locations depending mainly on antibiotic resistance. Recently, there has been suggestion that CYP2C19 genotype can have an effect on the efficacy of PPI due to the metabolizing activity and consequently affecting the eradicating

rate. This study was aimed to determine the efficacy of dual therapy as the first line H.pylori eradication therapy. Methods: Patients who had gastritis from gastroscopy with positive urease test were recruited. Additional gastric biopsy was taken for CYP2C19 genotypes. The dual therapy consisting of high dose Rabeprazole 20 mg qid and amoxicillin 1 gm tid was given for 10 days. We excluded those patients with penicillin allergy, receiving prior eradication therapy or antibiotic use within prior one month. All patients underwent 13C urea breath test (UBT) at least 6 weeks after eradication therapy. Results: A total of 72 patients with H.pylori associated gastritis were included. The regimen was well tolerated by all patients with no reported drop out. The eradication success rate as determined by negative UBT was achieved in 52/72 patients (72.2%).